GLAXO

** GlaxoSmithKline Pharmaceuticals GLAX.NS rises as much as 2.5% to 2,869 rupees; set to gain for second straight session

** Pharma co forays into oncology in India, with Jemperli and Zejula to treat gynaecological cancers

** More than 70,000 shares traded, below 30-day moving avg of 104,281

** GLAX last up ~1%, taking YTD gains to 24.3%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Aug 1 (Reuters) - Indian drugmaker GlaxoSmithKline Pharma GLAX.NS reported its first quarterly revenue decline in more than two years on Friday, leading to its shares declining the most in nearly four months.

The Indian unit of British drugmaker GSK Plc GSK.L reported a 2% decline in its revenue from operations to 8.05 billion rupees ($92 million)for the first quarter ended June 30.

GlaxoSmithKline Pharma said its performance during the quarter was "below anticipated levels," as it was hurt by "external factors such as seasonal disruptions".

The stock slumped 5.5% after results and was on track for its worst day since early April.

This is the company's first revenue drop since March 2023, when it grappled with lower prices of its key drugs due to the government's pricing cap.

Separately, in May, it had a temporary production disruption due to a fire at one of its contract manufacturing facilities, but did not disclose whether there was a financial impact from it.

Its quarterly profit climbed 12.5% on-year to 2.05 billion rupees as the company kept a tight lid on its expenses. Total expenses for the quarter dropped 5.2%.

($1 = 87.4090 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)

(([email protected]; 8800437922;))

June 19 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• RECEIVES TOTAL TAX DEMAND ORDER OF 30.7 MILLION RUPEES

Source text: ID:nBSE8hWFp3

Further company coverage: GLAX.NS

(([email protected];;))

April 11 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GETS TAX ORDER OF 216.3 MILLION RUPEES

Source text: [ID:]

Further company coverage: GLAX.NS

(([email protected];;))

** Shares of GlaxoSmithKline Pharmaceuticals GLAX.NS jump 12.4% to 2,266 rupees

** Drugmaker reports 35% Y/Y jump in third-quarter adjusted profit, rev up 18% Y/Y

** GLAX's profit growth driven by strong demand for its respiratory drugs and antibiotic Augmentin, while demand for its vaccines also boosted earnings

** Analysts' avg rating on GLAX at "buy"; median PT is 2,675.50 rupees - data compiled by LSEG

** Stock gained 19% in 2024

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Feb 14 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMA Q3 CONSOL PROFIT 2.3 BILLION RUPEES

• GLAXOSMITHKLINE PHARMA Q3 CONSOL REVENUE FROM OPERATIONS 9.49 BILLION RUPEES

• GLAXOSMITHKLINE PHARMACEUTICALS - RE-APPOINTMENT OF JUBY CHANDY AS CHIEF FINANCIAL OFFICER

Source text: ID:nBSE1JhsBH

Further company coverage: GLAX.NS

(([email protected];;))

Feb 5 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS - GOT TAX DEMAND ORDER OF 4.8 MILLION RUPEES

Source text: ID:nBSE836t2c

Further company coverage: GLAX.NS

(([email protected];))

** Shares of GlaxoSmithKline Pharma GLAX.NS rise 2% to 2,682 rupees

** The pharma co posted a 15% uptick in Q2 consol profit before tax to 3.44 bln rupees (~$41 mln)

** Rev for ops grew 5.6%, driven by strong demand for its generic drugs and vaccines

** Stock up 41% so far this year

($1 = 84.0770 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Oct 29 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• SEPT-QUARTER PROFIT 2.53 BILLION RUPEES

• SEPT-QUARTER REVENUE FROM OPERATIONS 10.11 BILLION RUPEES

• NUMBERS ARE IN CONSOLIDATED BASIS

• DIVIDEND 12 RUPEES PER SHARE

Source text: ID:nBSE4pH2MH

Further company coverage: GLAX.NS

(([email protected];))

Oct 15 (Reuters) - GlaxoSmithKline GLAX.NS sued Moderna MRNA.O in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

The lawsuit said Moderna's lipid nanoparticles for transporting mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccines.

(Reporting by Blake Brittain)

(([email protected];))

Sept 3 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GETS INCOME TAX REFUND ORDER FOR 2.22 BILLION RUPEES

Source text for Eikon: ID:nNSE6ckYJW

Further company coverage: GLAX.NS

(Reporting by VijayDattaram Malkar)

(([email protected];))

Aug 30 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS - GETS TAX ORDER OF 21 MILLION RUPEES, INTEREST 15 MILLION RUPEES

Further company coverage: GLAX.NS

(([email protected];))

Aug 26 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMA- ORDER FROM PUNJAB GST AUTHORITIES DROPPING PROCEEDINGS OF SHOW CAUSE NOTICE

Source text for Eikon: ID:nBSE3xk4Wb

Further company coverage: GLAX.NS

(([email protected];))

Aug 8 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS - GOT TAX DEMAND AGGREGATING TO 9.8 MILLION RUPEES

Source text for Eikon: ID:nBSE6gW1mq

Further company coverage: GLAX.NS

(([email protected];))

June 25 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GOT ORDER FROM GST OFFICE RAISING DEMAND OF 716.6 MILLION RUPEES

Further company coverage: GLAX.NS

(([email protected];))

BENGALURU, May 17 (Reuters) - Drugmaker GlaxoSmithKline Pharma India GLAX.NS reported a 49% rise in fourth-quarter adjusted profit on Friday, as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs.

The company reported consolidated profit before exceptional items and taxes of 2.68 billion rupees ($32.1 million) for the quarter ended March 31, compared to 1.80 billion rupees a year earlier.

In the year-ago period, the Indian unit of UK's GSK GSK.L had an exceptional charge of 104 million rupees which comprised restructuring and other costs.

The company's shares closed up 13.7% after the results.

Revenue from operations rose 18% to 9.30 billion rupees, led by a 12% growth in its generic medicines portfolio which the company attributed to key focus brands Augmentin, Ceftum and Calpol.

Earnings at drugmakers like GlaxoSmithKline Pharma and Abbott India ABOT.NS have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.

However, "despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share," the company said in a statement.

Last week, rival Abbott India reported a higher fourth-quarter profit, led by strong sales.

($1 = 83.3825 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)

(([email protected]; 8800437922;))

BENGALURU, May 9 (Reuters) - Indian drugmaker Abbott India ABOT.NS reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.

The company, which makes the popular antacid medicine Digene, said its profit rose to 2.87 billion rupees ($34.3 million) for the three months ended March 31, from 2.31 billion rupees a year earlier.

Revenues of drugmakers such as Abbott India and GlaxoSmithKline Pharma India GLAX.NS, which get most of their business from India, have been impacted after the inclusion of some of their drugs in the government's essential medicines list in September 2022, making them susceptible to price caps.

Abbott, which is a unit of U.S. healthcare firm Abbott Laboratories ABT.N, has been trying to mitigate the impact of pricing curbs by driving up sales and cutting back on expenses.

The company, which makes drugs including hypothyroidism treatment tablets Thyronorm, said its revenue from operations rose 7% to 14.39 billion rupees in the fourth quarter.

The company declared a dividend of 410 rupees per share for fiscal year 2024.

($1 = 83.4760 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)

(([email protected]; 8800437922;))

Adds response from BioNTech in paragraph 3

By Blake Brittain

April 25 (Reuters) - GlaxoSmithKline GLAX.NS sued Pfizer PFE.N and BioNTech 22UAy.DE in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

A Pfizer spokesperson said in a statement that the company is "confident in our IP position around Comirnaty" and intends to "vigorously defend" against GSK's claims. A BioNTech spokesperson declined to comment on the complaint.

A GSK spokesperson said the company believes its patents "provided the foundational technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines," and that it is "willing to license these patents on commercially reasonable terms and to ensure continued patient access" to the shots.

The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna against Pfizer in 2022.

Pfizer made $11.2 billion from sales of Comirnaty last year, while Moderna earned $6.7 billion in revenue from its vaccine Spikevax. Sales of both vaccines declined significantly last year from 2022.

London-based GSK asked the court for an unspecified amount of monetary damages from Pfizer and BioNTech that includes an ongoing patent-licensing fee.

GSK said in the complaint that its patents cover technology for transporting fragile mRNA into human cells that scientists began developing in 2008. GSK said it bought the rights to the inventions when it acquired part of Novartis' NOVN.S vaccines business in 2015.

GSK also sued Pfizer for patent infringement last year over technology used in Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo. Pfizer has denied GSK's claims in that case.

(Reporting by Blake Brittain
Editing by David Bario and Chizu Nomiyama and Franklin Paul)

(([email protected]))

BENGALURU, Feb 12 (Reuters) - GlaxoSmithKline Pharmaceuticals GLAX.NS, the Indian unit of the UK's GSK GSK.L, reported a 3% fall in third-quarter profit on Monday, hurt by the government's pricing cap on certain medicines.

Consolidated profit before exceptional items and tax for the quarter ended Dec. 31 was 2.29 billion rupees ($27.6 million), compared with 2.36 billion rupees a year earlier.

GlaxoSmithKline, which derives most of its revenue from India, continued to grapple with challenges following the inclusion of its key products such as Ceftum antibiotic and T-Bact ointment in the country's National List of Essential Medicines (NLEM) in September 2022, mandating sales below a government-set price ceiling.

It's revenue declined for three straight quarters following the adoption of the list before rebounding on the growth in its vaccine business in the June quarter of last fiscal year.

Revenue from operations rose a meagre 0.4% to 8.05 billion rupees in the latest quarter.

The company, which makes Augmentin antibiotic, incurred a one-time charge of 1.63 billion rupees, related to the cost of a voluntary retirement scheme and other employee dues.

It also had a one-time charge of 113.7 million rupees in the year-ago period, due to restructuring costs.

Last month, parent GSK beat market estimates for its fourth-quarter results and provided an upbeat forecast for 2024 and beyond, citing the expansion of its vaccines and cancer drugs pipeline.

Earlier this month, rival Abbott India ABOT.NS reported a 26% jump in third-quarter profit on elevated sales.

($1 = 82.9720 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Dhanya Ann Thoppil)

(([email protected];))

BENGALURU, Feb 1 (Reuters) - Pharmaceutical firm Abbott India ABOT.NS reported a 26% rise in third-quarter profit on Thursday, as higher sales outpaced the impact of a pricing cap on certain medicines.

The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier.

Revenues of drugmakers such as Abbott India, which get most of their business from India, continued to be affected during the quarter as some of their key drugs were included in the government's essential medicines list in September 2022, making them susceptible to price caps.

This was also highlighted by GlaxoSmithKline Pharma GLAX.NS in its previous earnings.

Abbott, which is a unit of U.S. healthcare firm Abbott Laboratories ABT.N, has been trying to mitigate the impact of pricing curbs by driving up sales and cutting back on expenses.

The company, which makes drugs including hypothyroidism treatment tablets Thyronorm, said its revenue from operations rose nearly 9% to 14.37 billion rupees.

Peer GlaxoSmithKline Pharma is set to report its December-quarter results next week.

Shares of Abbott India settled flat ahead of results.

($1 = 82.9510 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Sonia Cheema and Mrigank Dhaniwala)

(([email protected];))

** Shares of GlaxoSmithKline Pharmaceuticals GLAX.NS rise as much as 8.3% to a record 2,259 rupees; last up 4.9%

** Reuters could not immediately verify the reason for the move

** Stock last hit all-time highs in December while logging gains for 11 straight sessions

** Stock has risen about 5% twice so far in January and had risen about 5% thrice throughout 2023

** Avg analyst rating on GLAX stock is "hold", same as rival Dr Reddy's REDY.NS; Sun Pharma SUN.NS, Cipla's CIPL.NS avg rating is "buy" - LSEG data

** GLAX's avg PT is 1,686.5 rupees, 23% lower than current price - LSEG data

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD- GOT ORDER FOR GST DEMAND AT 10.7 MILLION RUPEES

Source text for Eikon: ID:nBSE4jZJMb

Further company coverage: GLAX.NS

Dec 27 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GOT ORDER FROM RAJASTHAN STATE GST AUTHORITIES

• ORDER FOR AGGREGATE DEMAND OF 9.3 MILLION RUPEES

Source text for Eikon: ID:nNSE5pZcmH

Further company coverage: GLAX.NS

(([email protected];))

Dec 26 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GST TAX OFFICERS VISITED CO CFA'S PREMISES IN CHENNAI & HOSUR ON DEC 24 FOR INSPECTION OF GOODS AND DOCUMENTS

• VISIT FOR SUPPRESS OF TRANSACTIONS RELATING TO SUPPLY OF GOODS AND / OR SERVICES UNDER GST

• NO IMPACT ON GSK

• RECEIVED ORDER DATED DEC 23 FROM ANDHRA PRADESH STATE GST AUTHORITIES DISALLOWING CERTAIN GST CREDITS

• RECEIVED ORDER DATED DEC 20 FROM WEST BENGAL CENTRAL GST AUTHORITIES

Source text for Eikon: ID:nBSE57kMTy

Further company coverage: GLAX.NS

(([email protected];))

Adds comments from some of the companies

ANKARA, Nov 30 (Reuters) - Turkey's competition authority said on Thursday it had launched an investigation into 19 pharmaceutical companies to determine whether they had violated competition law.

In a statement, the authority said it had decided on Nov. 9 to launch the probe into companies including AstraZeneca AZN.L, Bayer BAYGn.DE, Glaxosmithkline GLAX.NS, Johnson & Johnson JNJ.N, Bausch & Lomb BLCO.TO, Sanofi SASY.PA and Pfizer PFE.N. It provided no further details.

Asked about the matter, AstraZeneca said it does not comment on ongoing investigations as a matter of policy.

Glaxosmithkline, Sanofi and Germany's Merck KGaA MRCG.DE all said they were fully cooperating with competition authorities in Turkey, but did not elaborate further.

In a statement, BASF BASFn.DE said it was assessing the matter and was committed to high standards of legal compliance and business ethics.

AbbVie, Abdi Ibrahim, Bausch & Lomb, Bayer, Ilko, Johnson & Johnson, Liba, Menarini, Michael Page International, Panasonic, Pfizer, SIFI, and World Medicine could not immediately be reached for comment.

(Reporting by Ezgi Erkoyun, Huseyin Hayatsever, Ludwig Burger, and Patricia Weiss; Writing by Tuvan Gumrukcu; Editing by Sharon Singleton, Kirsten Donovan)

(([email protected];))

** Shares of GlaxoSmithKline Pharmaceuticals GLAX.NS rise as much as 6.2% to 1,675 rupees, highest since Jan. 24, 2022

** Reuters could not immediately ascertain the reason for the stock movement

** Stock has risen 13.7% since reporting Q2 profit climb on Nov. 9

** Over 553,000 shares change hands as of 3:26 p.m. IST, 5X the 30-day moving average

** Mean rating of five analysts is "hold"; median PT is 1,515 rupees - LSEG data

** Stock up 25% YTD

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Nov 16 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - APPROVED COMMERCIAL TRANSFORMATION INITIATIVE

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - WILL EXPLORE NEW INNOVATIVE SOLUTIONS INCLUDING OMNICHANNEL STRATEGY TO EXPAND ITS REACH AND COVERAGE TO TARGET SEGMENTS

• GLAXOSMITHKLINE PHARMACEUTICALS - LAUNCHED VOLUNTARY RETIREMENT SCHEME FOR COMMERCIAL FUNCTION EMPLOYEES

Source text for Eikon: ID:nBSE1x4wMG

Further company coverage: GLAX.NS

(([email protected];))

Corrects spelling of Managing Director's name in paragraph 5

BENGALURU, Nov 9 (Reuters) - GlaxoSmithKline Pharmaceuticals GLAX.NS reported a 12.5% rise in quarterly profit on Thursday as the Indian unit of UK's GSK plc saw strong demand for its vaccines and general medicine.

Consolidated profit for the quarter ended September 30 rose to 2.18 billion rupees ($26.18 million) from 1.93 billion rupees a year earlier.

Sales of general medicine grew 5% during the quarter, while those of vaccines rose 10% led by demand for its shingles vaccine, Shingrix, the company said in a statement.

Revenue from operations rose 4.4% to 9.57 billion rupees. Cost of materials consumed fell 31.2% during the quarter.

"We held leadership position for our key brands in relevant therapy areas such as anti-infectives and dermatology," said Bhushan Akshikar, managing director of GSK India.

GSK GSK.L raised its full-year profit and sales guidance for the second time after its third-quarter earnings beat expectations earlier this month. The raise in forecast is following the strong launch of its respiratory syncytial virus (RSV) vaccine in the United States

Shares in GSK India closed up 0.3% ahead of results on Thursday, where the Nifty Pharma index .NIPHARM. closed down 0.03% today.

($1 = 83.2810 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru; Editing by Nivedita Bhattacharjee)

(([email protected];))

Aug 31 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• ASSISTANT COMMISSIONER OF STATE TAX INITIATED SEARCH AT PREMISES OF CO

• BUSINESS OPERATIONS OF CO CONTINUE AS USUAL

Source text for Eikon: ID:nBSE9c1PPJ

Further company coverage: GLAX.NS

(([email protected];))